The ANA values the participation of our corporate partners and is supportive of the role that members of this community continue to play in our efforts to provide neurologists & neuroscientists with quality educational programs. These symposiums are not part of the ANA official educational program and the sessions and content are not endorsed by ANA.
Sunday, October 13, 2019
11:45 AM - 1:00 PM
Title: A Case Study: Progressive Muscle Weakness in a 31-Year-Old Female
Description: Participants are invited to work with us to uncover the cause of a patient’s symptoms in this interactive case study.
Margaret Frey, DO
Monday, October 14, 2019
6:00 AM – 7:30 AM
Title: Exploring the Science and Appreciating the Patient Experience: Early, Individualized Therapy to Optimize Outcomes in Multiple Sclerosis
Description: Multiple sclerosis (MS) is a progressive, immune-mediated, neurodegenerative disease that is associated with irreversible physical disability and functional impairment. Due to its heterogeneity, treatment of patients with MS is highly individualized. This activity is designed to help neurologists integrate the latest clinical evidence on disease-modifying therapies (DMTs) with patient needs and preferences to develop effective, individualized treatment plans. During this interactive case-based activity, learners will balance the benefits and risks of MS treatment options to optimize patient management through shared decision-making. For additional information including learning objectives, please go to https://integrityce.com/ana.
Registration: There is no additional fee to attend this symposium but registration is requested. Please click here or call Integrity Continuing Education, Inc. at 1-855-835-4004.
Aaron L. Boster, MD
Systems Medical Chief, Neuroimmunology
OhioHealth Neurological Physicians
Claire S. Riley, MD
Assistant Professor of Neurology
Clinical Director, Multiple Sclerosis Center
Columbia University Medical Center
New York, New York
Support: Supported by independent educational grants from Biogen MA, Inc. and Novartis Pharmaceuticals Corporation. This activity was supported by an educational grant from Celgene Corporation.